Daewoong Pharmaceutical, “It was not a criticism about serious errors related to Nabota”

In regards to the news about the FDA’s onsite inspection for ‘Nabora,’ Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced on the 24^th “The Daewoong Pharmaceutical’s Form 483 revealed at the FDA’s website is a document that is commonly issued about the status of manufacturer. Unlike it was mentioned in part of the media, it was not a problem which contains serious errors in our manufacturing p...